Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Dermapharm Holding SE's average Free Cash Flow per Share Growth Rate was 24.50% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -9.20% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 8.50% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 25.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Dermapharm Holding SE was 95.90% per year. The lowest was -22.60% per year. And the median was 12.10% per year.
Dermapharm Holding SE (CHIX:DMPd) 3-Year FCF Growth Rate Explanation
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Dermapharm Holding SE 3-Year FCF Growth Rate Related Terms
CHIX:DMPD vs ZTS, UTHR, VTRS: 3-Year FCF Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Dermapharm Holding SE's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dermapharm Holding SE 3-Year FCF Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dermapharm Holding SE's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Dermapharm Holding SE's 3-Year FCF Growth Rate falls into.
Dermapharm Holding SE 3-Year FCF Growth Rate Calculation
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of -9.20% mean?
Dermapharm Holding SE (CHIX:DMPD) has a 3-Year FCF Growth Rate of -9.20% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Dermapharm Holding SE and its competitors. According to the industry distribution chart, Dermapharm Holding SE ranks #455 out of 659 companies in the Drug Manufacturers industry, placing it in the top 69%.
Is Dermapharm Holding SE's 3-Year FCF Growth Rate too high?
Dermapharm Holding SE's current 3-Year FCF Growth Rate is -9.20%. Based on the distribution chart, Dermapharm Holding SE ranks #455 out of 659 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Dermapharm Holding SE has a GF Score™ of 80/100, reflecting its overall financial health beyond just this single metric.
How does Dermapharm Holding SE's 3-Year FCF Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Dermapharm Holding SE ranks #455 out of 659 companies for 3-Year FCF Growth Rate. This places Dermapharm Holding SE in the lower half of its industry. The industry median 3-Year FCF Growth Rate is 9.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Drug Manufacturers company?
The median 3-Year FCF Growth Rate among Drug Manufacturers companies is 9.00, based on 659 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Dermapharm Holding SE and its competitors. For the Drug Manufacturers industry, the median 3-Year FCF Growth Rate is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dermapharm Holding SE's current 3-Year FCF Growth Rate is -9.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dermapharm Holding SE stock overvalued right now?
Dermapharm Holding SE (CHIX:DMPD) has a current 3-Year FCF Growth Rate of -9.20%. The stock's GF Value™ is €44.50, compared to a current price of €38.63 — trading 13.2% below its estimated fair value. The current 3-Year FCF Growth Rate is -9.20%. Dermapharm Holding SE's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Dermapharm Holding SE (CHIX:DMPD), the current 3-Year FCF Growth Rate is -9.20% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dermapharm Holding SE (CHIX:DMPD) Overvalued in 2026?
Based on GuruFocus' analysis, Dermapharm Holding SE stock appears to be undervalued.
The current stock price of €38.63 is trading 13.2% below its estimated GF Value™ of €44.50.
Key valuation signals for CHIX:DMPD:
3-Year FCF Growth Rate: -9.20%
GF Value™: €44.50 vs. price of €38.63 (13.2% below fair value)
No single metric tells the full story. See the CHIX:DMPD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dermapharm Holding SE manufactures patent-free branded pharmaceuticals for selected therapy fields, over-the-counter drugs, and natural remedies. The portfolio of the company includes cosmetics, nutritional supplements, and diet and medical devices. Business operating segments include Branded pharmaceuticals, which drive key revenue, Other healthcare products, and Parallel import business. The Branded pharmaceuticals segment covers numerous product areas through a wide variety of items sold under reputable brand names.
80GF Score
Get the complete analysis for CHIX:DMPD
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DMPD has been successfully added to your 
